Berberine is also known as berberine hydrochloride. It is a typical member of the isoquinoline alkaloid family. In modern pharmacological research, it has attracted significant attention due to its diverse biological activities. These include antibacterial, antioxidant, and anti-inflammatory properties.
Furthermore, it exhibits prominent regulatory effects on glucose and lipid metabolism. In recent years, its multitarget intervention role in organ protection has become increasingly clear. This trend provides a new perspective for managing metabolic diseases and organ injury-related disorders.
This article systematically reviews the protective mechanisms of berberine on the liver, stomach, kidneys, intestines, and pancreas. It conducts an academic popular science analysis combined with experimental evidence.
1. Protective Effect of Berberine on the Liver: Focus on Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Injury Intervention
Nonalcoholic Fatty Liver Disease (NAFLD) is a liver pathological disease closely associated with metabolic syndrome. Therefore, it serves as a core research scenario for the hepatoprotective effects of berberine hydrochloride. Clinically, this compound can alleviate disease symptoms by reducing triglyceride (TG) and serum total cholesterol (TC) levels in NAFLD patients. The therapeutic process starts by improving insulin resistance (IR) through the regulation of glucose and lipid metabolism. Learn more about metabolic liver disorders from the World Health Organization (WHO).
1.1 Regulation of Lipid Metabolism and Excretion via Berberine Hydrochloride
In a rat NAFLD model induced by a high-fat diet, berberine hydrochloride can increase the levels of total bile acids in the liver and feces. It works by upregulating the expression of key molecules. These include hepatic cytochrome 7A1 (CYP7A1) and microsomal triglyceride transfer protein (MTTP).
At the same time, the substance downregulates the expression of liver X receptor alpha (LXRalpha) and sterol regulatory element-binding protein (SREBP). It also suppresses Niemann-Pick C1-like 1 (NPC1L1) and fatty acid synthase (FAS). This action inhibits fatty acid synthesis and the activity of the “intestinal-liver complex I.” Consequently, it dual-promotes fat metabolism and fecal lipid excretion.
1.2 Improvement of Hepatic Pathological Injury
Hepatic steatosis in NAFLD model rats is significantly alleviated by berberine hydrochloride. The ingredient also restores organizational structure disorder. It achieves this by inhibiting macrophage infiltration and neutrophil activation.
Furthermore, the treatment stops hepatic stellate cell activation and reduces proinflammatory macrophage polarization. Finally, it prevents abnormal extracellular matrix deposition in the liver. You can review similar botanical research updates on Frontiers in Pharmacology.
1.3 Activation of Energy Metabolism Pathways
In a high-fat diet mouse model, berberine hydrochloride can activate the hepatic AMPK/SIRT1 energy-sensing axis. This activation promotes PPARgamma deacetylation and the expression of thermogenic proteins.
As a result, it drives adipose tissue remodeling and reasonable fat distribution. The pathway also improves thermogenic function. This process indirectly reduces the metabolic burden on the liver.
1.4 Regulation of Intestinal Flora and Anti-Inflammation
In a genetically obese mouse model, berberine hydrochloride increases the abundance of beneficial bacteria in the cecal contents. These include Bifidobacterium and Akkermansia muciniphila. This change privileges the mitigation of hypertriglyceridemia and systemic inflammation.
For rats with hepatic ischemia-reperfusion injury, the compound can downregulate the expression of NLRP3 inflammasome-related proteins. These targets include NLRP3, ASC, and Caspase-1. This pathway directly reduces cell apoptosis.
1.5 Antagonism of Drug-Induced Hepatic Injury
Berberine hydrochloride protects against hepatotoxicity induced by methotrexate or areca nut water extract. It can reverse hepatic steatosis and dyslipidemia. Administering this agent accomplishes protection by downregulating the expression of p38-MAPK, NF-kappaB, and Kelch-like ECH-associated protein 1 (Keap1). It also reduces the expression of FAS and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR).
In addition, combination strategies can further enhance the therapeutic effect on NAFLD. For example, combining berberine hydrochloride with Pinus guineensis and gardenia coffee exerts a synergistic effect. This blend regulates miR-122, miR-34a, and the intestinal microbiome.
When combined with sitagliptin, the formula inhibits the p-ERK/ERK signal. It increases the expression of adiponectin receptor 2 (AdipoR2). This combination effectively promotes adipose tissue remodeling in hyperlipidemic rats.
2. Protective Effect of Berberine Hydrochloride on the Stomach: Hp Injury and Gastritis
The protective effect of berberine hydrochloride on the gastric mucosa focuses on three main pillars. These are anti-inflammation, anti-apoptosis, and the regulation of signaling pathways. It targets two core clinical scenarios: Helicobacter pylori (Hp) infection and chronic atrophic gastritis.
2.1 Alleviation of Hp-Induced Mucosal Epithelial Injury
In vitro experiments show that medium and high doses of berberine hydrochloride reverse the negative effects of Hp on human gastric mucosal epithelial GES-1 cells. It restores cell viability and inhibits cell apoptosis.
Furthermore, the compound reduces the secretion of IL-1beta/IL-8 and LDH activity. It simultaneously regulates the protein levels of p-ERK1/2, Bax (pro-apoptotic), and Bcl-2 (anti-apoptotic). The combination of berberine hydrochloride with the ERK1/2 inhibitor PD98059 enhances these protective effects. This confirms its mechanism relates closely to the regulation of the ERK1/2 pathway. For clinical overviews on Hp management, refer to WebMD Medical Insights.
2.2 Improvement of Chronic Atrophic Gastritis
In a rat model of chronic atrophic gastritis, berberine hydrochloride improves the pathological characteristics of gastric tissue. It reduces gastrin levels, inflammatory responses, and abnormal tissue proliferation. The alkaloid achieves this by inhibiting inflammatory factors like NF-kappaB, TNF-alpha, cyclooxygenase-2 (COX-2), IL-6alpha, IL-17a, and IFN-gamma.
It also downregulates the activity of the TGF-beta1/PI3K/Akt/mTOR/p70S6K signaling axis. At the same time, the molecule promotes the expression of protein tyrosine phosphatase (SHP-1) and the autophagy marker LC3II. This dual action successfully maintains gastric mucosal homeostasis.
3. Protective Effect of Berberine on the Kidneys: Covering Kidney Injury, Fibrosis, and Hyperuricemia-Related Renal Damage
The protective effect of berberine hydrochloride on the kidneys is characterized by multiple models and mechanisms. It covers diverse scenarios like renal tubular injury, drug-induced kidney injury, and renal fibrosis.
3.1 Protection of Renal Tubular Epithelial Cells
In a human renal cortical proximal tubular epithelial HK-2 cell injury model, berberine hydrochloride reduces the production of mitochondrial reactive oxygen species (ROS). It promotes the expression of the growth arrest-specific gene (GAS6).
At the same time, the supplement upregulates the expression of E-cadherin and downregulates NLRP3/Caspase-1. This action reduces Caspase-1 enzyme activity and IL-1beta secretion. Consequently, it alleviates severe cell injury. Explore peer-reviewed data on renal cellular pathways via the National Center for Biotechnology Information (NCBI).
3.2 Alleviation of Drug and Pathology-Induced Kidney Injury
In a rat kidney injury model induced by adriamycin, berberine hydrochloride alleviates tissue structure changes. It reduces the levels of urea and creatinine by lowering the expression of TGF-beta, Caspase-3, and NF-kappaB, while lessening oxidative stress.
For renal ischemia-reperfusion injury, it reduces serum chromium and blood urea nitrogen. The treatment also decreases the content of IL-1beta and TNF-alpha in the kidneys. It triggers this by inhibiting the SIRT1/Nrf2 signaling pathway and NLRP3/Caspase-1 expression.
For renal injury in hyperuricemic mice induced by potassium oxonate and hypoxanthine, the drug lowers serum uric acid, urea nitrogen, and creatinine. It accomplishes this by downregulating the activity of the NLRP3/Caspase-1/IL-1beta pathway.
3.3 Inhibition of Renal Fibrosis
In a mouse model of non-metabolic classic renal fibrosis, berberine hydrochloride downregulates the expression of renal alpha-smooth muscle actin (alpha-SMA, a fibrosis marker) and IL-1beta. It upregulates E-cadherin expression. The substance also alleviates glomerular compensatory hypertrophy, peritubular space widening, and inflammatory cell infiltration.
In addition, it can form a supramolecular self-assembly structure with aristolochic acid. This structure blocks the metabolism of aristolochic acid. It maintains the homeostasis of intestinal flora, reducing the risk of acute kidney injury.
4. Protective Effect of Berberine on the Intestines: From Infectious Diarrhea to Inflammatory Bowel Disease
The protective effect of berberine on the intestines focuses on three core areas. These are flora regulation, mucosal barrier maintenance, and anti-inflammatory analgesia. It effectively covers scenarios such as intestinal infection, irritable bowel syndrome (IBS), and ulcerative colitis (UC).
4.1 Inhibition of Pathogenic Bacteria and Flora Regulation
In vitro experiments confirm that berberine has a strong inhibitory effect on common intestinal pathogenic bacteria. These targets include Shigella dysenteriae, Shigella flexneri, Salmonella, and Staphylococcus aureus.
In an IBS rat model, it can increase the proportion of Lactobacillaceae and decrease Enterobacteriaceae in the intestine. This shift improves abnormal defecation, visceral hypersensitivity, and intestinal microinflammation. These findings confirm that flora regulation is a core protective mechanism.
4.2 Improvement of Inflammation and Mucosal Barrier in UC
In a mouse model of UC induced by dextran sulfate sodium (DSS), a high dose of berberine significantly reduces the disease activity index (DAI). It also lowers the colonic gross morphological damage index and the histological damage index. It works by downregulating TNF-alpha/IL-1beta and upregulating IL-10 (an anti-inflammatory factor).
At the same time, it increases the mRNA and protein expression of the tight junction protein claudin-1. This action maintains the structural stability of the intestinal mucosal junction complex. It reduces intestinal wall permeability, lowering the activation of local immune inflammatory responses. Furthermore, it inhibits the abnormal expression of intestinal stem cell markers. It prevents the destruction of tight junction proteins, maintaining the mechanical barrier to alleviate colonic inflammation.
4.3 Alleviation of Intestinal Stress-Related Pain
For irritable bowel syndrome characterized by visceral hypersensitivity, berberine significantly increases the pain threshold. It alleviates chronic visceral pain responses. This significant analgesic effect provides strong support for the comprehensive intervention of intestinal dysfunction.
5. Protective Effect of Berberine Berberine on the Pancreas: Severe Acute Pancreatitis
In a mouse model of severe acute pancreatitis, the protective effect of berberine focuses on anti-inflammation, anti-oxidation, and the inhibition of NF-kappaB activity. Compared with the untreated model group, the pancreatic mass index of mice in the berberine group was significantly reduced.
The serum levels of pro-inflammatory factors (IL-6, TNF-alpha) and oxidative stress markers (MDA) decreased. It also lowered MPO (an indicator of inflammatory infiltration), amylase, and lipase. Conversely, the levels of HO-1 (an antioxidant enzyme) and IL-10 (an anti-inflammatory factor) were significantly increased.
The mRNA expressions of TNF-alpha and IL-6 in pancreatic tissue were significantly downregulated. Meanwhile, the mRNA expressions of IL-10 and HO-1 were significantly upregulated. The protein expressions of HO-1, IkappaB-alpha, and NF-kappaBp65 were lowered, and the positive cell rate of NF-kappaBp65 was reduced. The results confirm that berberine alleviates pancreatic inflammatory and oxidative stress injury by activating HO-1. This mechanism relates closely to the inhibition of NF-kappaB activity.
Conclusion and Outlook
As a naturally derived multitarget drug, berberine exhibits clear protective effects on multiple organs like the liver, stomach, kidneys, intestines, and pancreas. It operates by regulating metabolic pathways (such as AMPK/SIRT1, TGF-beta/PI3K) and inflammatory signals (such as NF-kappaB, NLRP3). It also modulates apoptosis-related molecules (such as Bax/Bcl-2) and the intestinal flora. Its advantages lie in its broad mechanism of action and high safety profile from natural sources.
Furthermore, combination strategies can expand its therapeutic boundary. In the future, researchers will focus on the in-depth analysis of its molecular targets. They will optimize dosage forms to improve bioavailability and advance clinical trials. Berberine is expected to play an important clinical role in preventing and treating organ injury-related diseases, providing a new direction for the field of natural drug research.
References
- [1] Yu, H., & Du, J. L. (2020). Research Status of Pharmacological Effects and Mechanisms of Berberine. Chinese Journal of Modern Applied Pharmacy, 37(4), 501-507.
- [2] Chen, M. L., Li, Z. Q., Fan, Q. Q., et al. (2022). Research Progress on Pharmacological Effects and Related Mechanisms of Berberine. Chinese Traditional and Herbal Drugs, 53(18), 5861-5872.
Important Reminder: All content in this article is for general reference only and is provided solely to offer information support for practitioners in the nutrition and health industry. Descriptions related to efficacy are supported by corresponding data, but they do not represent claims or guidance for consumers. Content related to health, medical care, and technological applications is for reference only. For medical matters, please consult professional medical institutions and follow medical advice. This article does not provide any medical recommendations.